Our Partner Organizations
Operating under Open Science principles enables M4K to partner with a range of organizations that contribute their scientists’ expertise and research services. M4K is proud to be working with the following partners to develop a cure for DIPG.
If you are interested in partnering with M4K, please contact Owen Roberts, CEO, at [email protected]
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com
The Ontario Institute for Cancer Research (OICR) is a collaborative, not-for-profit research institute focused on accelerating the translation of new cancer research discoveries to patients around the world while maximizing the economic benefit of this research for the people of Ontario. Funding for OICR is provided by the Government of Ontario.
Reaction Biology Corporation (RBC) is a premiere CRO for early drug discovery services, including biochemical and biophysical screening and profiling techniques, assay development, protein production and cell-based assays. RBC has also added electrophysiology capability, including hERG patch clamping, screening, and other in vitro toxicity services. RBC holds the record for the largest collection of human active kinases (>600 targets) and epigenetic factors (>400 targets) for screening, profiling and MOA studies. RBC is one of the specialized Chemical Biology Centers for the NIH’s NExT program, performs NIH funded researches and provides early drug discovery solutions through collaborations. RBC has provided its services and proteins to over 1,000 customers worldwide, including large pharmaceutical, biotech, government, and academic labs. Contact Information: [email protected].
GL CHEMTEC INTERNATIONAL is a discovery-phase contract research company, delivering innovative custom solutions and technologies to the pharmaceutical, biotechnology, and materials science sectors since 2002. Count on GL CHEMTEC to be your trusted chemistry partner for complex synthetic route development and rapid scale-up from the milligram to the multi-kilogram level. We are flexible and responsive, offering both fixed cost and fee for service options to meet your drug discovery and development needs. We look forward to working with you! www.glchemtec.ca
M4K Pharma has brought together an experienced team to develop our first Medicines4Kids cure: a specific therapeutic for the orphan pediatric disease Diffuse Intrinsic Pontine Glioma (DIPG).
M4K’s founding team and partners include: leading scientists in DIPG research and the ALK2 drug target; entrepreneurs who have built and sold biotech companies; former industry scientists who are inventors of marketed medicines; experts in regulatory and intellectual property law; and clinicians responsible for caring for the children and unravelling the genetic drivers of the disease.